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Abstract:  Epithelial  carcinomas  of  the  ovary  exhibit  the  highest  mortality  rate  among 
gynecologic  malignancies.  Studies  found  that  the  metabolism  of  glycolipids  or 
carbohydrates is associated with acquirement of anticancer drug-resistance by cancer cells. 
This  study  was  to  characterize  possible  involvement  of  Lewis  Y  (Le
Y)  antigen  in  the 
drug-resistance  of  cancer  cells.  We  transfected  the  α1,2-fucosyltransferase  gene  into 
human ovarian carcinoma-derived RMG-1 cells and established RMG-1-hFUT cells with 
enhanced expression of Le
Y.  We  determined the  effects of docetaxel on the survival  of 
cells by MTT assaying and observed the apoptosis of cells in the presence of docetaxel by 
flow cytometric analysis and by transmission electron microscopy. Plasma membranes and 
intracellular  granules  in  RMG-1-hFUT  cells  were  stained  with  anti-Le
Y  antibody,  the 
intensity of the staining was higher than that in control cells. The RMG-1-hFUT cells 
exhibited higher resistance to docetaxel than the control cells with regard to the docetaxel 
concentration and time course. After treatment with 10 µg/mL docetaxel for  72  h,  the 
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control cells, but not RMG-1-hFUT, contained abundant positively stained cell debris due 
to disintegration of the cytoskeleton. On transmission electron microscopy, although the 
control  cells  treated  with  docetaxel  as  above  showed  the  following  morphology,  i.e., 
absence of villi, cells shrunken in size, pyknosis, agglutinated chromatin and cell buds 
containing  nuclei  in  the  process  of  apoptosis,  the  RMG-1-hFUT  cells  showed  only 
agglutinated chromatin and vacuoles in the cytoplasm. In  summary,  cells with enhanced 
expression  of  Le
Y  were  shown  to  acquire  docetaxel-resistance,  indicating  the  possible 
involvement of glycoconjugates in the drug-resistance. 
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1. Introduction 
Epithelial  carcinomas  of  the  ovary  exhibit  the  highest  mortality  rate  among  gynecologic 
malignancies,  that  is,  a  5-year  survival  rate  in  patients  treated  with  cytoreductive  surgery,  and 
combined with chemotherapy only 30–40%. Since the main reason for the failure of chemotherapy in 
the  patients  is  the  drug  resistance  of  cancer  cells,  clarification  of  the  mechanism  underlying  the 
resistance is required to improve the systemic treatments including chemotherapy for patients. The 
chemoresistance mediated by ATP-binding cassette (ABC) transporters, such as multidrug resistance 
(MDR) or multidrug resistance-associated protein (MRP) transporters, is mainly due to a decrease in 
the cellular accumulation of anticancer drugs due to extrusion of the drugs out of the cells through the 
transporters [1,2]. While, the resistance associated with glucosylation of ceramides is related to the 
removal  of  virulent  ceramides,  which  are  generated  from  sphingomyelin  on  activation  of 
sphingomyelinase in the anticancer drug-induced apoptotic pathway [3,4]. Also, enhanced expression 
of LacCer and Gb3Cer with 2-hydroxy fatty acids and longer carbohydrate chains, together with that of 
transporters,  was  characteristically  observed  in  paclitaxel-  and  cisplatin-resistant  ovarian 
carcinoma-derived cells [5], and GM3 and Le
b were found in paclitaxel-resistant cells [6], indicating 
that  the  metabolism  of  glycolipids  or  carbohydrates  is  associated  with  acquirement  of  anticancer 
drug-resistance by cancer cells. More directly, we previously demonstrated that transfection of the 
α1,2-fucosyltransferase  gene into ovarian  carcinoma-derived RMG-1 cells resulted in an increased 
amount of  Le
Y antigen  and enhanced  anticancer drug resistance  against 5-fluorouracil (5-FU) and 
carboplatin  [7,8].  In  fact,  Lewis-related  carbohydrate-structures  were  reported  to  be 
transformation-related antigens, that is, sialyl Le
a for the metastatic potential [9,10], and Le
b, Le
Y and 
H antigens for the grades of dysplasia and malignancy [11,12]. To further characterize the relationship 
between  Lewis  antigens  and  chemotherapeutic  resistance  of  ovarian  carcinoma-derived  cells,  we 
prepared RMG-1 cells exhibiting enhanced expression of Le
Y antigen by transfection with the FUT-1 
gene and compared their cell biological properties including resistance against docetaxel, which is a 
semi-synthetic taxol derivative whose cytotoxic effect involves promotion polymerization of tubulin 
and  inhibition  of  the  depolymerization  of  microtubules  for  three  times  longer  than  in  the  case   
of paclitaxel. Int. J. Mol. Sci. 2011, 12      7325 
 
   
2. Results 
2.1. Expression of Le
Y Antigen in Cells Transfected with the hFUT Gene 
On  immunocytochemical  staining  with  anti-Le
Y  antibody,  RMG-1-hFUT  cells  established  by 
transfection with the hFUT gene were found to express Le
Y antigen at a significantly higher level than 
the  original  RMG-1  cells  and  the  RMG-1(-)  cells  transfected  with  the  vector  alone,  and  the 
Le
Y-antigen in the RMG-1-hFUT cells were distributed in both the plasma membrane and intracellular 
granules (Figure 1). 
Figure 1. Immunocytochemical staining of cells with anti-LeY antibodies: (1) RMG-1-hFUT; 
(2) RMG-1; and (3) RMG-1(-). 
 
2.2. Effects of Docetaxel on the Survival Rates of Cells 
The relative survival rates of RMG-1, RMG-1(-) and RMG-1-hFUT cells cultured in the presence 
of  docetaxel  to  those  cultured  without  docetaxel  were  compared  as  functions  of  the  docetaxel 
concentration and time course. As shown in Figure 2, RMG-1-hFUT cells were more resistant against 
docetaxel  than  RMG-1  and  RMG-1(-)  cells,  and  the  concentrations  of  docetaxel  giving  the  half 
survival rates (IC50) were as follows, 7.98 ± 1.31 µg/mL for RMG-1-hFUT, 4.76 ± 1.42 µg/mL for 
RMG-1  and  4.60  ±  1.18  µg/mL  for  RMG-1(-).  Thus,  the  concentration  of  docetaxel  at  IC50  for 
RMG-1-hFUT cells was 1.7 times higher than those for RMG-1 and RMG-1(-) cells. Based on three 
separate experiments, the statistical significance of the docetaxel-resistance of RMG-1-hFUT cells as 
compared to that of RMG-1 and RMG-1(-) cells was evident, i.e., P < 0.05 and t = 2.88 and 3.34, 
respectively (Table 1). Int. J. Mol. Sci. 2011, 12      7326 
 
   
Figure  2.  Relative  survival  rates  of  cells  cultured  in  the  presence  of  docetaxel.  ○─○, 
RMG-1;  ▲─▲,  RMG-1(-);  ●─●,  RMG-1-hFUT.  (A)  cells  were  cultured  in  medium 
containing  different  concentrations  of  docetaxel  for  72  h;  (B)  cells  were  cultured  in 
medium containing 10 µg/mL docetaxel for various times. Viable cells were determined by 
MTT assaying and the relative survival rates were calculated in comparison to those of 
cells cultured without docetaxel.   
 
Table 1. Concentrations of docetaxel giving 50% survival rates (IC50) as determined by 
MTT  assaying.  Data  are  based  on  three  separate  experiments  and  the  relative 
docetaxel-resistance  of  RMG-1-hFUT  cells  was  compared  to  that  of  RMG-1  (a)  and 
RMG-1(-) (b) cells. Please check the highlighted cells. 
Cell line  IC50 (µg/mL)  t 
a  P
 a  t 
b  P
 b 
RMG-1-hFUT  7.98 ± 1.31  2.88  0.05  3.34  0.03 
RMG-1(-)  4.60 ± 1.18  0.16  0.88     
RMG-1  4.76 ± 1.42         
2.3. Docetaxel-Induced Apoptosis 
The frequency of apoptosis on cultivation of cells in the presence of docetaxel was determined by 
staining with annexin-V-FITC/PI, followed by flow cytometric analysis. As shown in Figure 3 and 
Table 2, RMG-1-hFUT cells after treatment with docetaxel at the concentration of 10 µg/mL for 72 h 
exhibited  a  significantly  lower  proportion  of  apoptotic  cells  than  RMG-1  and  RMG-1(-)  cells   
(P < 0.01), i.e., 65.3% for RMG-1-hFUT, 83.7% for RMG-1(-), and 82.2% for RMG-1. No significant 
difference was observed between those of RMG-1(-) and RMG-1 (P > 0.05). Then, cells stained with 
annexin-V-FITC/PI were examined under a fluorescence microscope. As shown in Figure 4, RMG-1 
and  RMG-1(-)  cells,  in  comparison  to  RMG-1-hFUT  ones,  were  intensively  stained  and  became 
smaller in size, and exhibited apoptosis with disintegration of the cytoskeleton generating cell debris, 
which exposed phosphatidyl serine, which is reactive with annexin V. The results clearly indicated that 
RMG-1-hFUT cells were more resistant against docetaxel than RMG-1 and RMG-1(-) cells. Int. J. Mol. Sci. 2011, 12      7327 
 
   
Figure 3. Flow cytometric analysis of cells after treatment with and without docetaxel. 
Cells cultured without (A) and with (B) docetaxel (10 µg/mL) for 72 h were stained with 
annexin-V-FITC/PI according to the manufacturer’s instructions and then analyzed with a 
FACS Calibur. (1) RMG-1-hFUT; (2) RMG-1; and (3) RMG-1(-). 
 
Table 2. Apoptotic cells after treatment with 10 µg/mL docetaxel, as analyzed by flow 
cytometry  after  staining  of  the  cells  with  annexin-V-FITC/PI.  Data  are  based  on  three 
separate experiments and the proportion of apoptotic cells for RMG-1-hFUT cells was 
compared to those of RMG-1 (a) and RMG-1(-) (b) cells. Please check the highlighted 
cells. 
Cell line  Apoptotic cells (%)  t 
a  P
 a  t 
b  P
 b 
RMG-1-hFUT  65.3 ± 2.1  7.42  0.006  9.50    0.002 
RMG-1(-)  83.7 ± 5.5  0.14  0.71     
RMG-1  82.2 ± 6.4         
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Figure 4. Immunofluorescence microscopy of cells stained with annexin-V- FICT/PI after 
treatment with and without docetaxel. Cells cultured without (A) and with (B) docetaxel 
(10 µg/mL) for 72 h were stained with annexin-V- FICT/PI and then examined under a 
fluorescence microscope (× 400). (1) RMG-1-hFUT; (2) RMG-1; and (3) RMG-1(-). 
 
2.4. Ultrastructure of Cells Examined by TEM 
Cells  not  treated  with  docetaxel  exhibited  a  similar  morphology  to  cancer  cells,  i.e.,  irregular 
shaped  cells,  abundant  microvilli  on  cell  surfaces,  large  number  of  intracellular  structures  in  the 
cytoplasm,  obvious  nucleolus,  uniform  chromatin,  and  a  rich  cytoplasm  (Figure  5).  RMG-1  and 
RMG-1(-) cells cultured in the presence of docetaxel showed the absence of villi, a decrease in size, 
pyknosis, agglutinated chromatin, and cell buds containing cell nuclei, and organs protruded out of the 
cell  surface,  and  apoptotic  bodies  were  finally  formed,  these  being  the  typical  morphological 
characteristics of cell apoptosis. In contrast, RMG-1-hFUT cells showed only agglutinated chromatin 
and  vacuoles  in  the  cytoplasm,  i.e.,  no  apoptotic  bodies,  indicating  suppression  of  the  process  of 
apoptosis by docetaxel. 
Figure 5. TEM of cells after treatment with and without docetaxel. Cells cultured without (A) 
and with (B) docetaxel (10 µg/mL) for 72 h were examined by TEM. (1) RMG-1-hFUT;   
(2) RMG-1; and (3) RMG-1(-). 
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3. Discussion 
Cell  surface  glycoconjugates  are  frequently  altered  in  association  with  transformation  and  are 
implicated in the malignancy of cancer cells, including their potential for metastasis and anticancer 
drug-resistance. As to ovarian carcinomas, Le
Y oligosaccharide, Fucα1-2Galβ1-4GlcNAc(3-1αFuc)-, 
which belongs to the lacto-series type 2 chain family, has been reported to be expressed in 60–90% of 
patients as a cancer-associated antigen, and its amount in cancer cells to be closely related with a poor 
prognosis [13]. We also observed that the quantity of Le
Y in primary ovarian carcinomas was similar to 
that in metastatic ones, and the more serious the malignancy, the higher the quantity of Le
Y antigen [7], 
as reported by others [14]. Also, an ovarian carcinoma-associated antigen, CA125, which has been 
widely applied for clinical diagnosis, contained the Le
Y-structure in its molecule [15], and accordingly 
an approach involving immunotherapy toward Le
Y as the target antigen was examined as a better 
therapeutic procedure, since conventional surgery and chemotherapy do not significantly increase the 
survival rate of ovarian cancer patients [16]. 
In our previous study [7], we established mutant cell lines of ovarian carcinoma-derived RMG-1 
cells by transfection of the α1,2-fucosyltransferase gene, and the resultant cells were found to contain a 
20 times higher amount of Le
Y-glycolipids than the original cells, and simultaneously to exhibit more 
malignant  behavior,  such  as  chemotherapeutic  drug-resistance  toward  5-FU  and  an  increased 
metastatic  potential  compared  to  the  original  cells.  The  involvement  of  α1,2-fucosyltransferase  in 
drug-resistance  toward  5-FU  has  also  been  reported  in  mice  treated  with  5-FU  and  human  colon 
carcinoma-derived  cells  with  5-FU-resistance,  but  H-2  and  Le
b  antigens  were  utilized  as  the 
drug-resistance-related glycoconjugates synthesized by α1,2-fucosyltransferase [17]. Since Le
x-glycolipids 
were contained in RMG-1 cells in a significantly higher amount, the major glycolipid synthesized on 
activation of α1,2-fucosyltransferase in RMG-1 cells was expected to be Le
Y-glycolipid [7], and also 
the same Le
Y-structure should be expressed on glycoproteins. Consequently, we attempted to establish 
RMG-1 cells with enhanced expression of Le
Y antigen at a higher level than previously attained by 
selection of Le
Y-positive cells with a flow cytometer, and successfully established RMG-1-hFUT cells 
exhibiting enhanced expression of Le
Y. 
On comparing the cellular behavior after treatment with docetaxel of RMG-1-hFUT cells with that 
of control cells, RMG-1-hFUT cells were found to exhibit stronger drug-resistance than control cells. 
RMG-1-hFUT cells exposed to 10 µg/mL docetaxel for 72 h showed only agglutinated chromatin and 
vacuoles in the cytoplasm, i.e., they did not produce apoptotic bodies, on analysis by TEM, whereas 
the progress of apoptosis was evidently observed in the control cells treated under the same conditions. 
Also, reduced apoptosis of RMG-1-hFUT cells treated with docetaxel, in comparison to that of control 
cells, was observed on staining with annexin-V-FITC/PI, followed by fluorescence microscopy and 
flow cytometry. Thus, enhanced expression of Le
Y on transfection of the α1,2-fucosyltransferase gene 
was associated with the drug-resistance against docetaxel and also that against carboplatin and 5-FU, 
providing a molecular marker of the drug-resistance. 
The mechanism of Le
Y antigen’s effect on drug resistance needs further research. Modification of 
the activity of epidermal growth factor receptor (EGFR), which is the glycoprotein with Le
Y in the 
carbohydrate structure [18], was thought to be one of the mechanisms. EGFR is a tyrosine kinase, 
which  is  highly  expressed  in  ovarian  cancers,  and  activates  the  PI3K-MAPK  pathway  leading  to Int. J. Mol. Sci. 2011, 12      7330 
 
   
protein kinase-B (PKB) and Bcl-2-phosphorylation. The EGFR-mediated signal transduction pathway 
was revealed to be inhibited by anti-Le
Y antibodies, which leads to apoptosis of cancer cells [19]. In 
this connection, inhibitors of PI3K and JAK2 inhibit Le
Y and H-mediated endothelial cell formation in 
the process of angiogenesis, indicating the involvement of  Le
Y  and the H-structure in the  growth 
factor-mediated signal transduction pathway [14]. We obtained proof of the high MRP-1 promoter 
activity  observed  in  the  presence  of  EGF  in  the  transfection  assays,  supported  an  effect  at  the 
transcription level [20]. According to the reports, the PI3K pathway known to release free E2 factor 
(E2F) [21], and the results of Lee H’s research showed that E2F is the activator of Topo I  mRNA’s 
transcription [22]. CD44 is another cytomembrane protein with Fucα1-2Galβ1-4GlcNAc(3-1αFuc)-, 
which play an important role in cell adhesion and signal transduction. Multidrug resistance protein-2 
(MRP-2) expression was induced in H322/CD44s cells cultured on hyaluronan. It also resulted in the 
transcription of MDR-1 and the expression of P-glycoprotein on lymphocytes in a dose-dependent 
manner. Research showed CD44 correlation with the expression of PKC-α [23]. Wang [24] found that 
all cell signal pathways were activated including increased expression or phosphorylation of PKB and 
PKN in α1,3-FucT-VII overexpressing human H7721 hepatocarcinoma cell line by transfecting the 
cDNA of α1,3-fucosyltransferases-VII (α1,3-FucT-VII) into the cell line. The same discovery showed 
up in our experiments by oligonucleotide microarray. Compared with RMG-1, there were 88 genes 
with  different  expressions  in  RMG-1-hFUT.  After  investigating  the  different  expressed  genes,  we 
found  RMG-1-hFUT  cells  showed  obvious  alterations  in  protein  binding,  nucleotide  binding,  cell 
proliferation,  DNA-dependent  regulation  of  transcription,  signal  transduction,  protein  amino  acid 
phosphorylation,  transcription,  cell  adhesion  [25].  We  presume  that  the  changes  of  content  and 
composing component of glycan chain on cell surface occurred after we transfected the cDNA of 
FUT1 which possibly induced or up-regulated the expression of resistance-related protein genes by 
several signal transduction pathways. Our experiments displayed that Le
Y antigen could improve the 
resistance of carcinoma cells to chemotherapeutics by boosting the corpuscular activity. So the drug 
resistance of ovarian carcinoma-derived RMG-1 cells with enhanced expression of Le
Y antigen is the 
result of multidrug resistant mechanisms combined action. 
4. Materials and Methods 
4.1. Materials 
The following reagents were purchased from commercial sources: expression vector pcDNA3.1(-) 
and a TA cloning kit from Invitrogen (San Diego, CA, USA), E. coli (competent cells) JM109 from 
Toyobo (Tokyo, Japan), restriction endonucleases, BamHI, EcoRI, and G418 (geneticin) from Gibco, 
cell transfection and NucleoBond plasmid kits from GE Healthcare (Piscataway, NJ, USA), AmpliTaq 
Gold
TM and a Bigdye
TM terminator cycle sequencing ready reaction kit from Perkin-Elmer/Applied 
Biosystems (Foster City, CA, USA), an immunocytochemical SABC kit from Boshide Biotech Co 
(Wuhan, China), a mouse monoclonal anti-Le
Y antibody from Santa Cruz (CA, USA), docetaxel from 
Shandong Qilu Pharmaceutical Co. Ltd (China), Dulbecco’s modified Eagle’s medium (DMEM) and 
fetal bovine serum (FBS) from Hyclone (Logan, UT, USA), trypsin, ethylenediamine tetraacetic acid   Int. J. Mol. Sci. 2011, 12      7331 
 
   
(EDTA), and 3(4,5-dimethyl-2-thiazolyl)-2,5-diphenyl tetrazolium (MTT) from Amresco (Solon, OH, 
USA), and an annexin-V-FITC/PI kit from Jingmei Biotech Co., Ltd. (Shenzhen, China). 
4.2. Cell Culture 
Human ovarian carcinoma (clear cell type)-derived RMG-1 cells and their transfectants, RMG-1(-) 
and RMG-1- hFUT cells, were cultured in DMEM containing 10% FBS, 100 U/mL penicillin and   
0.1 mg/mL streptomycin in a humidified incubator at 37 °C under a 5% CO2 atmosphere. 
4.3. Transfection of the Fucosyltransferase Gene 
The human α1,2-fucosyltransferase gene (FUT-1) was amplified by PCR with human leukocyte 
genomic DNA as a template and primers according to the human FUT-1 gene sequence (GenBank 
Accession  Number:  M35531),  sense  primer,  5’-CATGTGGCTCCGGAGCCATCGTC-3’,  and 
antisense  primer,  5’-GCTCTCAAGGCTTAGCCAATGTCC-3’,  under  the  following  conditions: 
denaturation at 94 °C for 9 min, followed by 25 cycles of 94 °C, 1 min, 65 °C, 1.5 min, and 72 °C, 
2 min, and then extension at 72 °C for 10 min. The PCR products were ligated into the PCR 2.1 vector 
to  clone  FUT-1  gene,  and  its  DNA  sequence  was  determined  by  means  of  the  dideoxynucleotide 
chain-termination method with the BigDye terminator cycle sequenceing ready reaction kit and a DNA 
sequencer  (ABI  Genetic  Analyzer;  Perkin-Elmer/Applied  Biosystems).  Then  the  FUT-1  gene  in 
pCR2.1 was cut out by digestion with restriction enzymes, BamHI and EcoRI, and ligated into the 
BamHI and EcoRI sites of the pcDNA3.1 vector (pcDNA3.1-hFUT). pcDNA3.1-hFUT and the vector 
alone were transfected into RMG-1 cells with a vector transfection kit, according to the instructions for 
the kit to establish RMG-1-hFUT and RMG-1(-) cells, respectively. The resultant transfectants were 
initially  selected  by  cultivation  with  medium  containing  an  aminoglycoside  antibiotic,  G418,  at   
400 µg/mL concentration, and were maintained at 200 µg/mL for 15 days. Finally, RMG-1-hFUT cells 
exhibiting significantly higher expression of Le
Y-structure than that of the original RMG-1 and the 
RMG-1(-)  cells  were  selected  by  flow  cytometry  using  a  FACS  Calibur,  with  monoclonal   
anti-Le
Y antibodies. 
4.4. Immunocytochemical Assaying 
RMG-1,  RMG-1(-)  and  RMG-1-hFUT  cells  cultured  in  chamber  slides  were  fixed  with  4% 
paraformaldehyde  and  then  stained  according  to  the  instructions  for  the  SABC  kit.  The  primary 
antibody,  mouse  monoclonal  anti-Le
Y  antibody,  biotin-labeled  goat  monoclonal  anti-mouse  IgG 
antibody and alkaline phosphatase-labeled avidin were used at 1:100 dilution, and specimens were 
observed under a light microscope (IX71, Olympus, Tokyo, Japan). 
4.5. Cell Viability Determined by MTT Assaying 
Cell  suspensions  (3  ×  10
3 cells/200  µL)  were  inoculated  into  the  wells  of  a  96-well  plate  and 
cultured for 20 h, followed by cultivation in the medium containing docetaxel at concentrations of 1, 2, 
5, 10, 20, 50 and 100 µg/mL for 72 h,
 and also in the medium containing 10 µg/mL docetaxel for 
different periods, 12 h, 24 h, 48 h, 72 h and 96 h. Then, 20 µL of MTT (5 mg/mL) was added and the Int. J. Mol. Sci. 2011, 12      7332 
 
   
plate was incubated for 4 h, and the resultant formazan in the viable cells was dissolved with 150 µL of 
dimethyl sulfoxide with a horizontal oscillator until visible purple crystalline matter was dissolved 
completely. The optical density of each well was determined at 570 nm with a ELISA monitor (Sunrise 
RC TS TC, Tecan). The assays were repeated three times, and the concentrations of docetaxel giving 
the IC50 were determined. 
4.6. Flow Cytometry 
To compare the ratios of apoptosis and necrosis for RMG-1, RMG-1(-) and RMG-1-hFUT cells 
after treatment with docetaxel, cells cultured in the medium containing 10 µg/mL docetaxel for 72 h 
were stained with the annexin-V-FITC/PI kit according to the instructions, and then analyzed by flow 
cytometry (FACS Calibur) and fluorescence microscopy (IX71, Olympus). 
4.7. Transmission Electron Microscopy (TEM) 
Cells (1 × 10
6 cells) cultured in the medium containing 10 µg/mL docetaxel for 72 h were fixed with 
2.5% glutaraldehyde for 2 h. After washing the cells with phosphate-buffered saline (PBS), sections 
for TEM were prepared as follows, fixation with 1% osmium tetroxide at 4 °C for 30 min, dehydration 
with several concentrations of acetone, embedding with Epon812, preparation of ultra thin slices, and 
staining  with  uranyl  acetate  and  lead  acetate,  followed  by  examination  at  ×  6000  by  TEM 
(JEM-1200EX, JEOL, Tokyo, Japan). 
5. Conclusions 
In summary, cells with enhanced expression of Le
Y were shown to acquire docetaxel-resistance, 
indicating the possible involvement of glycoconjugates in drug-resistance. 
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